| Abstrakt: |
A study conducted at Henan University of Science and Technology in China evaluated the efficacy and safety of combining the immune checkpoint inhibitor camrelizumab with concurrent chemoradiotherapy (CCRT) for the treatment of locally recurrent esophageal cancer. The study enrolled 14 patients, and the results showed a 69.2% objective response rate and a 100% disease control rate. The median progression-free survival was 7.6 months, and the median overall survival was 18.6 months. Adverse events were reported in all patients, with 57.1% experiencing grade 3 adverse events. The study concluded that the combination treatment showed promising efficacy and acceptable safety. Further data will be reported in the future. [Extracted from the article] |
